Breaking News

The company, which also said it is short on funds, may have to pay $18.3 million to Hudson Bay Master Fund if forebearance is not granted for the default.

Developers can use the Zika virus samples to ascertain whether their tests can help distinguish Zika infection from similar diseases.

Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.

Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.

The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.

The company plans to use proceeds to further invest in its development of molecular testing and other strategies in the preventive medicine space.

Researchers used mass spectrometry to identify unique biochemical markers that differentiate Lyme disease from southern tick-associated rash Illness.

The offering consists of two tranches of $600 million each, and the firm plans to use the net proceeds for general corporate purposes, including the repayment of outstanding senior notes due on Aug. 23. 

The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.

The firm said it may use the loans to finance its $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics.

The company said it will use the funds to expand its menu of STI tests and launch its io rapid diagnostic platform into UK sexual health clinics.

The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.

As part of the contract, Abbott will supply analytical equipment and consumables, including the Alinity ci and Alinity h series diagnostics instruments.

The decline reflects a drop off in sales of its ColonSentry colorectal cancer blood test and other diagnostics.

The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.

The firm is approaching launch of its lung cancer test with new sales hires planned, but saw its Q2 net loss miss the consensus Wall Street estimate.

The diagnostic firm plans to sell the shares to BTIG. It also has granted the investment bank the option to purchase up to an additional 375,000 shares. 

The company may use the proceeds of the loans to help fund the $7.2 billion acquisition of Patheon. The loan facility follows a $1.5 billion senior notes offering by Thermo Fisher last week.

The scientists argued that studies indicate the creatine kinase-myocardial band testing has no "incremental value to patient care" and outlined steps to put the test to rest.

The ThromboSeq test detected early-stage cancer with 81 percent accuracy and late-stage cancer with 88 percent accuracy.

Roche's HbA1c test, along with an immunoassay system from Shenzhen New Industries Biomedical, and a celiac test from Immco also received 510(k) clearance last month. 

The PCR-based test can simultaneously detect for the Zika virus, all serotypes of the dengue virus, the chikungunya virus, the West Nile virus, and a host gene. 

The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.

Pages